Nada Babović

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

The pre-metastatic niche: finding common ground

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials

Coordinated regulation of myeloid cells by tumours

IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction

The hypoxic tumor microenvironment: A driving force for breast cancer progression

Advances in the treatment of neurofibromatosis-associated tumours

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

Neutrophils in cancer: neutral no more

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Molecular mechanisms and clinical applications of angiogenesis

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Natural product and natural product derived drugs in clinical trials

Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy

Role of NKG2D and its ligands in cancer immunotherapy.

Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients

Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients

Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3–CD16+ NK cells

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

The Stage Dependent Changes in NK Cell Activity and the Expression of Activating and Inhibitory NK Cell Receptors in Melanoma Patients

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Phase II trial of pirfenidone in adults with neurofibromatosis type 1